Jane Prior sold $2.6M of COCO
Chief Marketing Officer at Vita Coco Company, Inc.. 50,000 shares at an average of $52.92, traded Mar 5, 2026, filed Mar 9, 2026.
Score components
- +15RoleOfficer
- +25Trade size$2.6M at market
- +10Share of holdings soldSold 28% of holdings
- +15Cluster8 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -6.8%, 3m +39.2%, 6m +4.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001482981-26-000060, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 5, 2026 | FTax withholding Common Stock10b5-1 | -1,458 | $55.18 | $80k | 128,104 | Mar 9, 2026 |
| Mar 5, 2026 | FTax withholding Common Stock10b5-1 | -705 | $55.18 | $39k | 127,399 | Mar 9, 2026 |
| Mar 5, 2026 | MOption exercise Common Stock10b5-1 | +3,675 | $10.18 | $37k | 131,074 | Mar 9, 2026 |
| Mar 5, 2026 | MOption exercise Common Stock10b5-1 | +23,750 | $10.18 | $242k | 154,824 | Mar 9, 2026 |
| Mar 5, 2026 | MOption exercise Common Stock10b5-1 | +22,575 | $10.18 | $230k | 177,399 | Mar 9, 2026 |
| Mar 5, 2026 | SOpen-market sale Common Stock10b5-1 | -34,159 | $52.73 | $1.8M | 143,240 | Mar 9, 2026 |
| Mar 5, 2026 | SOpen-market sale Common Stock10b5-1 | -15,741 | $53.32 | $839k | 127,499 | Mar 9, 2026 |
| Mar 5, 2026 | SOpen-market sale Common Stock10b5-1 | -100 | $54.08 | $5,408 | 127,399 | Mar 9, 2026 |
| Feb 20, 2026 | AGrant or award Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | +14,025 | $16.91 | $237k | 14,025 | Mar 9, 2026 |
| Mar 5, 2026 | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -3,675 | $0.00 | $0 | 0 | Mar 9, 2026 |
| Mar 5, 2026 | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -23,750 | $0.00 | $0 | 0 | Mar 9, 2026 |
| Mar 5, 2026 | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -22,575 | $0.00 | $0 | 4,725 | Mar 9, 2026 |
Related signals
Other insiders at Vita Coco Company, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 24Weak | Vita Coco Company, Inc. | Kenneth Sadowsky director | $323k 3,900 shares | -1% | |
| 45Moderate | Vita Coco Company, Inc. | Ira Liran director | $12M 148,074 shares | -39% | |
| 35Weak | Vita Coco Company, Inc. | Jonathan Burth Chief Operating Officer | $2.4M 30,000 shares | -34% | |
| 45Moderate | Vita Coco Company, Inc. | Ira Liran director | $15M 191,926 shares | -40% | |
| 34Weak | Vita Coco Company, Inc. | Charles van Es Chief Commercial Officer | $604k 8,045 shares | -12% | |
| 24Weak | Vita Coco Company, Inc. | Kenneth Sadowsky director | $302k 3,900 shares | -1% | |
| 35Weak | Vita Coco Company, Inc. | Jonathan Burth Chief Operating Officer | $2.3M 30,000 shares | -34% | |
| 35Weak | Vita Coco Company, Inc. | Jonathan Burth Chief Operating Officer | $1.4M 20,000 shares | -26% | |
| 34Weak | Vita Coco Company, Inc. | Charles van Es Chief Commercial Officer | $599k 8,561 shares | -11% | |
| 21Weak | Vita Coco Company, Inc. | Charles van Es Chief Commercial Officer | $134k 2,000 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.